Adjuvant Mucosal Strategies Confer Safe and Effective Immunity Against Mycoplasma pneumoniae and Overcome Vaccine-Associated Enhanced Lung Pathology
Our findings suggest that IM immunization with CQ-adjuvanted inactivated vaccines may represent a suboptimal strategy for MP, given the risk of exacerbating lung immunopathology. Conversely, a mucosal immunization approach using the FLA-ST adjuvant demonstrates considerable promise, offering an effective balance between bacterial clearance and an improved safety profile, highlighting its potential for future MP vaccine development.
Authors
- Cunbao Liu (ORCID: https://orcid.org/0000-0002-2101-2612)
- Jingping Hu (ORCID: https://orcid.org/0000-0001-5548-1241)
- Ning Luan (ORCID: https://orcid.org/0000-0001-8559-7464)
- Dandan Gao (ORCID: https://orcid.org/0000-0002-2035-8769)
- Xiaolong Zhang (ORCID: https://orcid.org/0000-0002-6109-9783)
- Han Cao (ORCID: https://orcid.org/0000-0002-5226-218X)
- Yifan Zhou (ORCID: https://orcid.org/0000-0001-6082-0148)
- Zhentao Lei
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3390/vaccines13090968
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71